Series | Date | Patients (n) | Advanced primary or recurrent | IORT modality | Median IORT dose (Gy) | Crude LRR | Median survival (mos) | OS |
---|---|---|---|---|---|---|---|---|
Hicks et al [18]. | 1993 | 13 | Recurrent | Orthovoltage | 15 | 7/13 | 7 | - |
Konski et al [24]. | 1993 | 8 | Primary | IOERT | 20 | 7/8 | 27 | - |
 |  | 5 | Recurrent | IOERT | 20 | - | 9 | - |
Gerard et al [17]. | 1994 | 20 | Primary | IOERT | - | 4/20 | - | 75% at 18 mos |
 |  | 34 | Recurrent | IOERT | - | 6/34 | - | 32% at 4 yrs |
Stelzer et al [23]. | 1995 | 22 | Recurrent | IOERT | 22 | 10/22 | 26 | 43% at 5Â yrs (CSS) |
Mahé et al [19]. | 1996 | 70 | Recurrent | IOERT | 19 | 50/67 | 11 | 8% at 3 yrs |
del Carmen et al [14]. | 2000 | 5 | Recurrent | IOERT | 15 | 2/5 | - | - |
Gemignani et al [16]. | 2001 | 9 | Recurrent | HDR-BT | 14 | - | - | 54% at 3Â yrs |
Martinez-Monge et al [20]. | 2001 | 31 | Primary | IOERT | 12 | 6/31 | - | 58% at 10Â yrs |
 |  | 36 | Recurrent | IOERT | 15 | 18/36 | - | 14% at 10 yrs |
Roth et al [21]. | 2003 | 1 | Recurrent | HDR-BT | 15 | 0/1 | 20 | - |
Tran et al [22]. | 2007 | 17 | Recurrent | Orthovoltage | 11.5 | - | - | 47% at 5Â yrs (CSS) |
Current series | 2012 | 13 | Primary | IOERT | 12.5 | 4/13 | 13 | 29% at 3Â yrs |
 |  | 73 | Recurrent | IOERT | 17.5 | 33/73 | 17 | 25% at 3 yrs |